CRISPR Therapeutics AG: Shareholders approved amendments to the Company's articles of association; amended and restated Articles of Association become effective upon registration in the Swiss Commercial Register on or about June 5, 2026, subject to approval by the Swiss Federal Commercial Authority (effective 2026-06-05).
“On June 4, 2026, at the Annual Meeting, the shareholders of the Company approved amendments to the articles of association of the Company (the “Articles of Association”) as described in the Company’s Proxy Statement. The Company’s amended and restated Articles of Association become effective upon registration in the Commercial Register in the canton of Zug, Switzerland on or about June 5, 2026, subject to the approval by the Swiss Federal Commercial Authority.”
Shareholder Votes
CRISPR Therapeutics AG shareholders approved Non-Binding Advisory Vote on the 2025 Compensation Report (under Swiss statutory compensation report) at the 2026-06-04 meeting.
“The endorsement of the 2025 Compensation Report was approved on a non-binding basis. The results of the non-binding vote were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES NUMBER 39,906,651 8,704,469 143,733 22,498,855”
Shareholder Votes
CRISPR Therapeutics AG shareholders approved Re-election of Members of the Compensation Committee at the 2026-06-04 meeting.
“Ali Behbahani, M.D., H. Edward Fleming, Jr., M.D., John T. Greene and Briggs W. Morrison, M.D. were each duly re-elected as members of the Company’s Compensation Committee of the Board of Directors. The results of the election were as follows: NOMINEE FOR AGAINST ABSTAIN BROKER NON-VOTES Ali Behbahani, M.D. 35,458,908 13,198,641 97,304 22,498,855 H. Edward Fleming Jr., M.D. 46,322,476 2,341,513 90,864 22,498,855 John T. Greene 46,319,646 2,326,146 109,061 22,498,855 Briggs W. Morrison, M.D. 45,317,635 3,329,265 107,953 22,498,855”
Shareholder Votes
CRISPR Therapeutics AG shareholders approved Re-election of Members to the Board of Directors and the Chairman at the 2026-06-04 meeting.
“Samarth Kulkarni, Ph.D., Ali Behbahani, M.D., Maria Fardis, Ph.D., H. Edward Fleming Jr., M.D., Simeon J. George, M.D., John T. Greene, Katherine A. High, M.D., Sandesh Mahatme, LL.M., Briggs W. Morrison, M.D., Christian Rommel, Ph.D. and Douglas A. Treco, Ph.D. were each duly re-elected as members of the Company’s Board of Directors and Samarth Kulkarni, Ph.D. was duly re-elected as the chairman of the Company’s Board of Directors. The results of the election were as follows: NOMINEE FOR AGAINST ABSTAIN BROKER NON-VOTES Samarth Kulkarni, Ph.D. 47,043,987 1,628,226 82,640 22,498,855 Ali Behbahani, M.D. 35,498,392 13,174,523 81,938 22,498,855 Maria Fardis, Ph.D. 47,804,457 874,207 76,189 22,498,855 H. Edward Fleming Jr., M.D. 46,977,636 1,686,127 91,090 22,498,855 Simeon J. George, M.D. 47,435,748 1,225,519 93,586 22,498,855 John T. Greene 46,876,367 1,793,109 85,377 22,498,855 Katherine A. High, M.D. 47,779,619 899,787 75,447 22,498,855 Sandesh Mahatme, LL.M. 46,268,964 2,405,580 80,30”
Shareholder Votes
CRISPR Therapeutics AG shareholders approved Discharge of the Members of the Company's Board of Directors and Executive Committee at the 2026-06-04 meeting.
“The discharge of the members of the Company's Board of Directors and the Executive Committee from personal liability for their activities during the year ended December 31, 2025 was approved. The results of the vote were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES NUMBER 48,379,678 262,761 112,414 22,498,855”
Shareholder Votes
CRISPR Therapeutics AG shareholders approved Approval of the Appropriation of Financial Results at the 2026-06-04 meeting.
“The proposal to carry forward the net loss resulting from the appropriation of financial results was approved. The results of the vote were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES NUMBER 70,554,606 415,599 283,503 0”
Shareholder Votes
CRISPR Therapeutics AG shareholders approved Approval of the Swiss Management Report, the Consolidated Financial Statements and the Statutory Financial Statements of the Company for the Year Ended December 31, 2025 at the 2026-06-04 meeting.
“The Swiss management report, the consolidated financial statements and the statutory financial statements of the Company for the year ended December 31, 2025 were approved. The results of the vote were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES NUMBER 70,716,663 288,652 248,393 0”
Earnings Releases
CRISPR Therapeutics AG reported first quarter 2026 results: revenue $43 million.
“CASGEVY generated first quarter 2026 revenue of $43 million.”
Equity Issuances
CRISPR Therapeutics AG issued 11,363,580 Common Shares may be delivered upon conversion of the Notes of convertible note to qualified institutional buyers for $600.0 million aggregate principal amount of Convertible Senior Notes due 2031.
“any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 1.01. Entry into a Material Definitive Agreement. On March 16, 2026, CRISPR Therapeutics AG (the “Company”) completed its previously announced private offering (the “Offering”) of $600.0 million aggregate principal amount of its Convertible Senior”
Material Agreements
CRISPR Therapeutics AG entered into Indenture with U.S. Bank Trust Company, National Association valued at $600.0 million aggregate principal amount (effective 2026-03-16).
“On March 16, 2026, CRISPR Therapeutics AG (the “Company”) completed its previously announced private offering (the “Offering”) of $600.0 million aggregate principal amount of its Convertible Senior Notes due 2031 (the “Notes”)”
Debt Financings
CRISPR Therapeutics AG incurred convertible notes of $600.0 million aggregate principal amount with U.S. Bank Trust Company, National Association at effective coupon of 1.125%, increased to 1.7308% maturing March 1, 2031.
“On March 16, 2026, CRISPR Therapeutics AG (the “Company”) completed its previously announced private offering (the “Offering”) of $600.0 million aggregate principal amount of its Convertible Senior Notes due 2031 (the “Notes”)”
Governance Changes
CRISPR Therapeutics AG: Shareholders approved amendments to the Articles of Association, as described in the Proxy Statement, effective upon registration in the Commercial Register in Zug, Switzerland on or about June 6, 2025 (effective 2025-06-06).
“On June 5, 2025, at the 2025 Annual General Meeting of Shareholders (the “Annual Meeting”), the shareholders of CRISPR Therapeutics AG (the “Company”) approved amendments to the articles of association of the Company (the “Articles of Association”) as described in the Company’s proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 16, 2025 (the “Proxy Statement”).”
Julianne Bruno resigned as Chief Operating Officer at CRISPR Therapeutics AG.
“On March 24, 2025, Julianne Bruno informed CRISPR Therapeutics AG (the “Company”) that she would be stepping down from the Company to pursue external opportunities, effective as of April 11, 2025, and she resigned from her position as Chief Operating Officer of the Company.”
Julianne Bruno was appointed as Chief Operating Officer at CRISPR Therapeutics AG.
“On May 23, 2024, CRISPR Therapeutics AG (the “Company”) announced the promotion of Julianne Bruno, currently the Company’s Senior Vice President and Head of Programs & Portfolio, to be the Company’s Chief Operating Officer effective as of May 23, 2024.”
Earnings Releases
CRISPR Therapeutics AG reported financial results for first quarter ended March 31, 2024.
“On May 8, 2024, CRISPR Therapeutics AG announced its financial results for the quarter ended March 31, 2024”
Earnings Releases
CRISPR Therapeutics AG reported financial results for the fourth quarter ended December 31, 2023.
“CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results”
Earnings Releases
CRISPR Therapeutics AG reported financial results for the year ended December 31, 2023.
“On February 21, 2024, CRISPR Therapeutics AG announced its financial results for the year ended December 31, 2023 and other business highlights.”
Material Agreements
CRISPR Therapeutics AG entered into Investment Agreement with certain institutional investors valued at $280 million (effective 2024-02-13).
“On February 13, 2024, CRISPR Therapeutics AG (the “Company”) entered into an investment agreement (the “Investment Agreement”) with certain institutional investors relating to the issuance of 3,916,082 shares of the Company’s common shares, par value of CHF 0.03 per share (the “Common Shares”), to such investors (the “Offering”).”
Phuong Khanh Morrow resigned as Chief Medical Officer at CRISPR Therapeutics AG.
“On December 14, 2023, Phuong Khanh Morrow, M.D., FACP resigned as Chief Medical Officer of CRISPR Therapeutics AG (the “Company”) to be effective as of January 26, 2024.”
Material Agreements
CRISPR Therapeutics AG amended Amendment No. 1 with Vertex Pharmaceuticals Incorporated and Vertex Pharmaceuticals (Europe) Limited (effective 2023-12-12).
“On December 12, 2023, CRISPR Therapeutics AG, CRISPR Therapeutics Limited, CRISPR Therapeutics, Inc., and TRACR Hematology Ltd (together, “CRISPR”) entered into an amendment to the Amended and Restated Joint Development and Commercialization Agreement (the “Amendment No. 1”) with Vertex Pharmaceuticals Incorporated and Vertex Pharmaceuticals (Europe) Limited (together, “Vertex”), related to the global development, manufacturing, and commercialization of exagamglogene autotemcel, or exa-cel (formerly CTX001).”
Earnings Releases
CRISPR Therapeutics AG reported financial results for the third quarter ended September 30, 2023.
“CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the third quarter ended September 30, 2023.”
Rodger Novak resigned as President and Chairman at CRISPR Therapeutics AG.
“On September 7, 2023, CRISPR Therapeutics AG (the “Company”) announced that Rodger Novak, M.D. tendered his resignation as President of the Company as well as a director and Chairman of the Company’s Board of Directors (the “Board”), and all such resignations to be effective as of September 15, 2023 (the “Resignation Date”).”
Earnings Releases
CRISPR Therapeutics AG reported financial results for quarter ended June 30, 2023.
“On August 7, 2023, CRISPR Therapeutics AG announced its financial results for the quarter ended June 30, 2023 and other business highlights.”
Governance Changes
CRISPR Therapeutics AG: Amended and restated Articles of Association approved by shareholders, effective upon registration with Swiss commercial authorities on or about June 9, 2023 (effective 2023-06-09).
“The Company’s amended and restated Articles of Association become effective upon registration in the Commercial Register in the canton of Zug, Switzerland on or about June 9, 2023, subject to the approval by the Swiss Federal Commercial Authority.”
Shareholder Votes
CRISPR Therapeutics AG shareholders approved Endorsement of the 2022 Compensation Report at the 2023-06-08 meeting.
“The endorsement of the 2022 Compensation Report was approved on a non-binding basis. The results of the non-binding vote were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES NUMBER 26,387,171 15,034,482 142,276 16,807,924”
Shareholder Votes
CRISPR Therapeutics AG shareholders approved Approval of the grant of equity for members of the Executive Committee from the Annual Meeting to the 2024 annual general meeting of shareholders at the 2023-06-08 meeting.
“The grant of equity for members of the Executive Committee from the Annual Meeting to the 2024 annual general meeting of shareholders was approved on a binding basis. The results of the binding vote were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES NUMBER 27,342,115 14,113,037 108,777 16,807,924”
Shareholder Votes
CRISPR Therapeutics AG shareholders approved Approval of the total variable compensation for members of the Executive Committee for the current year ending December 31, 2023 at the 2023-06-08 meeting.
“The total variable compensation for members of the Executive Committee for the current year ending December 31, 2023 was approved on a binding basis. The results of the binding vote were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES NUMBER 31,310,823 10,126,213 126,893 16,807,924”
Shareholder Votes
CRISPR Therapeutics AG shareholders approved Approval of the total non-performance related compensation for members of the Executive Committee from July 1, 2023 to June 30, 2024 at the 2023-06-08 meeting.
“The total non-performance related compensation for members of the Executive Committee from July 1, 2023 to June 30, 2024 was approved on a binding basis. The results of the binding vote were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES NUMBER 31,071,592 10,363,680 128,657 16,807,924”
Shareholder Votes
CRISPR Therapeutics AG shareholders approved Approval of the grant of equity for members of the Board of Directors from the Annual Meeting to the 2024 annual general meeting of shareholders at the 2023-06-08 meeting.
“The grant of equity for members of the Board of Directors from the Annual Meeting to the 2024 annual general meeting of shareholders was approved on a binding basis. The results of the binding vote were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES NUMBER 28,523,942 12,922,502 117,485 16,807,924”
Shareholder Votes
CRISPR Therapeutics AG shareholders approved Approval of the total non-performance-related compensation for members of the Board of Directors from the Annual Meeting to the 2024 annual general meeting of shareholders at the 2023-06-08 meeting.
“The total non-performance-related compensation for members of the Board of Directors from the Annual Meeting to the 2024 annual general meeting of shareholders was approved on a binding basis. The results of the binding vote were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES NUMBER 41,036,078 389,401 138,450 16,807,924”
Shareholder Votes
CRISPR Therapeutics AG shareholders approved Election or Re-election of the Members of the Compensation Committee at the 2023-06-08 meeting.
“Proposal 5 –Election or Re-election of the Members of the Compensation Committee Ali Behbahani, M.D., H. Edward Fleming, Jr., M.D., Simeon J. George, M.D., and John T. Greene, were each duly elected and re-elected, as applicable, as members of the Company’s Compensation Committee of the Board of Directors. The results of the election were as follows: NOMINEE FOR AGAINST ABSTAIN BROKER NON-VOTES Ali Behbahani, M.D. 22,931,018 18,555,470 77,441 16,807,924 H Edward Fleming Jr., M.D. 39,628,150 1,854,312 81,467 16,807,924 Simeon J. George, M.D. 39,578,104 1,906,247 79,578 16,807,924 John T. Greene 38,619,814 2,829,336 114,779 16,807,924”
Shareholder Votes
CRISPR Therapeutics AG shareholders approved Re-election of the Members and Chair of the Board of Directors at the 2023-06-08 meeting.
“Proposal 4 – Re-election of the Members and Chair of the Board of Directors Rodger Novak, M.D., Samarth Kulkarni, Ph.D., Ali Behbahani, M.D., Maria Fardis, Ph.D., H. Edward Fleming Jr., M.D., Simeon J. George, M.D., John T. Greene, Katherine A. High, M.D., and Douglas A. Treco, Ph.D. were each duly re-elected as members of the Company’s Board of Directors and Rodger Novak, M.D. was duly re-elected as the chairman of the Board of Directors. The results of the election were as follows: NOMINEE FOR AGAINST ABSTAIN BROKER NON-VOTES Rodger Novak, M.D. 41,225,578 270,501 67,850 16,807,924 Samarth Kulkarni, Ph.D. 40,484,397 1,013,593 65,939 16,807,924 Ali Behbahani, M.D. 23,098,811 18,392,522 72,596 16,807,924 Maria Fardis, Ph.D. 41,210,171 285,063 68,695 16,807,924 H Edward Fleming Jr., M.D. 40,927,328 564,987 71,614 16,807,924 Simeon J. George, M.D. 40,902,631 589,614 71,684 16,807,924 John T. Greene 40,337,357 1,152,556 74,016 16,807,924 Katherine A. High, M.D. 41,120,246 374,090 69,593 16”
Shareholder Votes
CRISPR Therapeutics AG shareholders approved Discharge of the Members of the Board of Directors and Executive Committee at the 2023-06-08 meeting.
“Proposal 3 – Discharge of the Members of the Board of Directors and Executive Committee The discharge of the members of the Company’s Board of Directors and the Executive Committee from personal liability for their activities during the year ended December 31, 2022 was approved. The results of the vote were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES NUMBER 41,154,717 325,296 83,916 16,807,924”
Shareholder Votes
CRISPR Therapeutics AG shareholders approved Approval of the Appropriation of Financial Results at the 2023-06-08 meeting.
“Proposal 2 – Approval of the Appropriation of Financial Results The proposal to carry forward the net income resulting from the appropriation of financial results was approved. The results of the vote were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES NUMBER 57,987,144 188,211 196,498 0”
Shareholder Votes
CRISPR Therapeutics AG shareholders approved Approval of the Swiss Management Report, the Consolidated Financial Statements and the Statutory Financial Statements of the Company for the Year Ended December 31, 2022 at the 2023-06-08 meeting.
“Proposal 1 – Approval of the Swiss Management Report, the Consolidated Financial Statements and the Statutory Financial Statements of the Company for the Year Ended December 31, 2022 The Swiss management report, the consolidated financial statements and the statutory financial statements of the Company for the year ended December 31, 2022 were approved. The results of the vote were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES NUMBER 58,042,258 156,560 173,035 0”
Earnings Releases
CRISPR Therapeutics AG reported financial results for first quarter ended March 31, 2023.
“CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the first quarter ended March 31, 2023.”
Bradley Bolzon resigned as director at CRISPR Therapeutics AG.
“On March 28, 2023, Bradley Bolzon, Ph.D. notified the Board of Directors of CRISPR Therapeutics AG (the “Company”) of his intention to resign as a director of the Company, effective as of the close of business on March 28, 2023.”
Material Agreements
CRISPR Therapeutics AG entered into Non-Exclusive License Agreement with Vertex Pharmaceuticals Incorporated valued at $100.0 million (effective 2023-03-23).
“On March 23, 2023, CRISPR Therapeutics AG (“CRISPR”) entered into a Non-Exclusive License Agreement (the “Non-Ex License”) with Vertex Pharmaceuticals Incorporated (“Vertex”), pursuant to which CRISPR agreed to license to Vertex, on a non-exclusive basis, certain of its gene editing intellectual property to exploit certain products for the diagnosis, treatment or prevention of diabetes type 1, diabetes type 2 or insulin dependent/requiring diabetes throughout the world.”
Raju Prasad was appointed as Chief Financial Officer at CRISPR Therapeutics AG.
“On March 13, 2023, CRISPR Therapeutics AG (the “Company”) announced the hiring and appointment of Raju Prasad, Ph.D. as its Chief Financial Officer, effective March 14, 2023.”
Earnings Releases
CRISPR Therapeutics AG reported financial results for the fourth quarter and full year ended December 31, 2022.
“On February 21, 2023, CRISPR Therapeutics AG announced its financial results for the quarter and year ended December 31, 2022 and other business highlights.”
Earnings Releases
CRISPR Therapeutics AG reported third quarter ended September 30, 2022 results: revenue $0.1 million.
“Revenue: Total collaboration revenue was $0.1 million for the third quarter of 2022, compared to $0.3 mill”
Lawrence O. Klein resigned as Chief Operating Officer at CRISPR Therapeutics AG.
“On October 27, 2022, Lawrence O. Klein, Ph.D. resigned from his position as Chief Operating Officer of CRISPR Therapeutics AG.”
Tony W. Ho was terminated as Executive Vice President, Research and Development at CRISPR Therapeutics AG.
“On December 14, 2021, Tony W. Ho was terminated from his position as Executive Vice President, Research and Development of CRISPR Therapeutics AG (the “Company”).”
Brendan Smith was appointed as Senior Vice President and Chief Financial Officer at CRISPR Therapeutics AG.
“On October 14, 2021, CRISPR Therapeutics AG (the “Company”) announced the hiring and appointment of Brendan Smith as its Senior Vice President and Chief Financial Officer, effective immediately.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.